251 related articles for article (PubMed ID: 32948911)
21. Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [
Kluge K; Einspieler H; Haberl D; Spielvogel C; Stoiber S; Vraka C; Papp L; Wunsch S; Egger G; Kramer G; Grubmüller B; Shariat S; Hacker M; Kenner L; Haug A
J Nucl Med; 2024 Jan; 65(1):63-70. PubMed ID: 38050125
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
23. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
24. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.
Fendler WP; Schmidt DF; Wenter V; Thierfelder KM; Zach C; Stief C; Bartenstein P; Kirchner T; Gildehaus FJ; Gratzke C; Faber C
J Nucl Med; 2016 Nov; 57(11):1720-1725. PubMed ID: 27261520
[TBL] [Abstract][Full Text] [Related]
27. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
Rauscher I; Maurer T; Souvatzoglou M; Beer AJ; Vag T; Wirtz M; Weirich G; Wester HJ; Gschwend JE; Schwaiger M; Schottelius M; Eiber M
Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
[TBL] [Abstract][Full Text] [Related]
28. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
29. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
30. Repeatability of
Seifert R; Sandach P; Kersting D; Fendler WP; Hadaschik B; Herrmann K; Sunderland JJ; Pollard JH
J Nucl Med; 2022 May; 63(5):746-753. PubMed ID: 34446454
[TBL] [Abstract][Full Text] [Related]
31. Correlations between whole body volumetric parameters of
Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
[TBL] [Abstract][Full Text] [Related]
32. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
33. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
34.
Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):477-482. PubMed ID: 32696091
[TBL] [Abstract][Full Text] [Related]
35.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
36.
Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
[TBL] [Abstract][Full Text] [Related]
37. Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET/CT images in newly diagnosed prostate cancer patients.
Erdogan EB; Tekce E; Koca S; Aslan N; Toluk O; Aydin M
Nucl Med Commun; 2024 Jul; 45(7):629-641. PubMed ID: 38835183
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
[TBL] [Abstract][Full Text] [Related]
39. Detection Rate of
Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
[TBL] [Abstract][Full Text] [Related]
40. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
